ABCL · Healthcare
Abcellera Biologics Inc
16/100
Smart-money confidence1 of 3 sources positive
Bearish — money moving out
No standout activity across the feeds we track.
Hedge funds
22
Congress
No data
Insiders
No data
Cross-source blend of hedge-fund breadth, Congress trades, and insider Form 4s. ·
how the score works
Market cap
$3.5B
Industry
Biotechnology
Sector
Healthcare
Exchange
NasdaqGS
About ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals…
Who's behind the signal
Every informed buyer we can see on ABCL, across all three feeds.
Hedge funds · 4
Tudor Investment (Paul Tudor Jones)
Increased +27%
Point72 (Steve Cohen)
Increased +18%
Citadel Advisors
Decreased −26%
Millennium Management (Englander)
Decreased −27%
Congress · 0
No congressional trades on record.
Insiders
No significant Form 4 insider activity in the window.
Not a model pick — but on our radar.
ABCELLERA BIOLOGICS INC isn't in the top-10 model right now, but 4 tracked investors hold it. Everything below is real signal from public filings — treat this as a watch candidate, not a conviction call.
4
Investors
0
New positions
2
Increasing
2
Decreasing
0
Unchanged
Price History
Loading price data...
Return:
High:
Low:
Who's Holding This Stock
Position sizes and recent activity from tracked institutional investors
Trust weight: 1.2×
% of portfolio
0.0%
Position change
+27%
0.0% of Tudor Investment's portfolio
Trust weight: 1.1×
% of portfolio
0.0%
Position change
+18%
0.0% of Point72's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−26%
0.0% of Citadel Advisors's portfolio
Trust weight: 1.0×
% of portfolio
0.0%
Position change
−27%
0.0% of Millennium Management's portfolio
Portfolio Allocation
How much of each investor's portfolio is allocated to ABCELLERA BIOLOGICS INC
⚠ Disclaimer: This page is for informational purposes only. Holdings data from SEC EDGAR 13F filings, delayed up to 135 days. Not a recommendation to buy or sell ABCELLERA BIOLOGICS INC or any security.
订阅每周更新
我们每周会把巴菲特、达利欧、阿克曼以及另外 47 位传奇投资人正在买入的股票发送给你 — 免费，直接来自他们的 SEC 申报文件。
永久免费 · 无垃圾邮件 · 随时退订